CoChat

Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials

Zhang, Bo, Wu, Qiong, Zhou, You Lang, Guo, Xinyu, Ge, Jun, Fu, Jiaji · 2018 · International Immunopharmacology
Cited by 103

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: Although available evidence from clinical trials has shown that immune checkpoint inhibitors (ICIs) combination therapy can lead to a series of immune‐related adverse events (irAEs), the overall risk of irAEs on combination therapy has yet not been systematically reported. Therefore, we performed a meta‐analysis to comprehensively explore the overall risks for irAEs on combination immunotherapy. Methods: PubMed, Embase, and Google Scholar were systematically searched for relevant randomized controlled trials (RCTs) comparing combination immunotherapy to monotherapy. The meta‐analysis was conducted by using Review Manager 5.3. Results: A total of 11 RCTs involving 5307 patients were eligible for this meta‐analysis. The risk ratio for all‐grade diarrhea and all‐grade colitis for combination therapy was 1.95 (95% CI 1.54, 2.46; P < 0.00001) and 4.45 (95% CI 3.04, 6.51; P < 0.00001), respectively. The risk ratio for all‐grade hyperthyroidism and all‐grade hypothyroidism for combination therapy was 2.84 (95% CI 1.71, 4.72; P < 0.0001) and 1.71 (95% CI 1.38, 2.13; P < 0.00001), respectively. The risk ratio for all‐grade increased AST and all‐grade increased ALT was 3.87 (95% CI 2.74, 5.47; P < 0.00001) and 4.29 (95% CI 3.05, 6.04; P < 0.00001), respectively. The risk ratio for all‐grade hypophysitis and all‐grade pneumonitis was 4.24 (95% CI 2.26, 7.98; P < 0.00001) and 2.92 (95% CI 1.60, 5.33; P = 0.0005), respectively. Conclusions: Patients receiving combination immunotherapy are at increased risk of selected all‐grade irAEs. Although fatal high‐grade irAEs is rare, AEs caused by combination immunotherapy should be recognized promptly in order to avoid more serious complications. HighlightsThis is the first and most comprehensive meta‐analysis on the risk of various irAEs following ICIs on combination therapy.Combination immunotherapies are associated with a significant increase in risk of selected all‐grade irAEs.Some fatal irAEs such as pneumonitis and hepatotoxicity should be recognized promptly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.intimp.2018.08.014

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 29

  1. Siegel, 2016, Cancer statistics, 2016, CA Cancer J. Clin., 66, 7
  2. Wu, 2017, The clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety, Int. J. Cancer, 141, 2562, 10.1002/ijc.31012 · DOI
  3. Momtaz, 2014, Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway, Pharmgenomics Pers. Med., 7, 357
  4. Postow, 2015, Immune Checkpoint Blockade in Cancer Therapy, J. Clin. Oncol., 33, 1974, 10.1200/JCO.2014.59.4358 · DOI · Paper page
  5. Preusser, 2015, Prospects of immune checkpoint modulators in the treatment of glioblastoma, Nat. Rev. Neurol., 11, 504, 10.1038/nrneurol.2015.139 · DOI · Paper page
  6. Saresella, 2012, The PD-1/PD-L1 pathway in human pathology, Curr. Mol. Med., 12, 259, 10.2174/156652412799218903 · DOI
  7. Xu, 2018, The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer, Int. J. Cancer, 142, 2344, 10.1002/ijc.31252 · DOI
  8. Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 · DOI · Paper page
  9. Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 · DOI · Paper page
  10. Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 · DOI · Paper page
  11. Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol., 18, 312, 10.1016/S1470-2045(17)30065-7 · DOI · Paper page
  12. Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 · DOI · Paper page
  13. Younes, 2016, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol., 17, 1283, 10.1016/S1470-2045(16)30167-X · DOI · Paper page
  14. Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466 · DOI · Paper page
  15. Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 · DOI · Paper page
  16. Hao, 2017, Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials, Medicine (Baltimore), 96, 10.1097/MD.0000000000007325 · DOI
  17. Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 · DOI · Paper page
  18. Wei, 2017, Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: a meta-analysis of randomized clinical trials, Medicine (Baltimore), 96, 10.1097/MD.0000000000008931 · DOI
  19. Di Giacomo, 2010, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications, Semin. Oncol., 37, 499, 10.1053/j.seminoncol.2010.09.007 · DOI · Paper page
  20. Tandon, 2018, The risk of diarrhea and colitis in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis, J. Immunother., 41, 101, 10.1097/CJI.0000000000000213 · DOI
  21. Boutros, 2016, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nat. Rev. Clin. Oncol., 13, 473, 10.1038/nrclinonc.2016.58 · DOI · Paper page
  22. Murakami, 2016, Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma, Clin. Kidney J., 9, 411, 10.1093/ckj/sfw024 · DOI · Paper page
  23. Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
  24. Omuro, 2018, Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143, Neuro-Oncology, 20, 674, 10.1093/neuonc/nox208 · DOI · Paper page
  25. Long, 2018, Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study, Lancet Oncol., 19, 672, 10.1016/S1470-2045(18)30139-6 · DOI · Paper page
  26. Higgins, 2011, The Cochrane collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
  27. Wu, 2017, The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy, Biotarget, 1, 7, 10.21037/biotarget.2017.05.02 · doi:10.21037/biotarget.2017.05.02
  28. Khalil, 2016, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Nat. Rev. Clin. Oncol., 13, 273, 10.1038/nrclinonc.2016.25 · DOI · Paper page
  29. Nishino, 2016, Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis, JAMA Oncol., 2, 1607, 10.1001/jamaoncol.2016.2453 · DOI · Paper page

Cited by

See all 103

Metadata

Authors
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J.
Venue
International Immunopharmacology
Publisher
Elsevier BV
Published
2018-10
Volume
63
Pages
292-298
ISSN
1567-5769 (ISSN-L)
OpenAlex
W2885781276
Cited by
103
References
18
FWCI
1.62
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.